CN1095375C - Medicated cosmetics capable of being used to treat primary and secondary varicose vein simultaneously and its preparation - Google Patents
Medicated cosmetics capable of being used to treat primary and secondary varicose vein simultaneously and its preparation Download PDFInfo
- Publication number
- CN1095375C CN1095375C CN98126710A CN98126710A CN1095375C CN 1095375 C CN1095375 C CN 1095375C CN 98126710 A CN98126710 A CN 98126710A CN 98126710 A CN98126710 A CN 98126710A CN 1095375 C CN1095375 C CN 1095375C
- Authority
- CN
- China
- Prior art keywords
- weight
- aluminum
- allantoin
- varicosis
- bulbus allii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 3
- 206010046996 Varicose vein Diseases 0.000 title abstract description 5
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 66
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 28
- 229960000458 allantoin Drugs 0.000 claims abstract description 28
- 239000002674 ointment Substances 0.000 claims abstract description 21
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000839 emulsion Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000000758 substrate Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- NUCLJNSWZCHRKL-UHFFFAOYSA-N allantoic acid Chemical compound NC(=O)NC(C(O)=O)NC(N)=O NUCLJNSWZCHRKL-UHFFFAOYSA-N 0.000 claims description 24
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 17
- 229910052782 aluminium Inorganic materials 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 14
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 241000234282 Allium Species 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000470 constituent Substances 0.000 claims description 8
- HSEYYGFJBLWFGD-UHFFFAOYSA-N 4-methylsulfanyl-2-[(2-methylsulfanylpyridine-3-carbonyl)amino]butanoic acid Chemical compound CSCCC(C(O)=O)NC(=O)C1=CC=CN=C1SC HSEYYGFJBLWFGD-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- ZFFOTPBKJPSNHU-UHFFFAOYSA-J [Al+3].C(=O)([O-])C(O)C(O)C(=O)[O-].[Na+].C(C)(=O)O.C(=O)([O-])C(O)C(O)C(=O)[O-] Chemical compound [Al+3].C(=O)([O-])C(O)C(O)C(=O)[O-].[Na+].C(C)(=O)O.C(=O)([O-])C(O)C(O)C(=O)[O-] ZFFOTPBKJPSNHU-UHFFFAOYSA-J 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 8
- 208000025865 Ulcer Diseases 0.000 abstract description 5
- 239000000654 additive Substances 0.000 abstract description 5
- 230000000996 additive effect Effects 0.000 abstract description 5
- 230000003796 beauty Effects 0.000 abstract description 5
- 239000000419 plant extract Substances 0.000 abstract description 5
- 231100000397 ulcer Toxicity 0.000 abstract description 5
- 201000004624 Dermatitis Diseases 0.000 abstract description 3
- 206010048768 Dermatosis Diseases 0.000 abstract description 3
- 208000017520 skin disease Diseases 0.000 abstract description 3
- 241001214984 Crinum thaianum Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 6
- 230000036560 skin regeneration Effects 0.000 description 6
- 206010020565 Hyperaemia Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- RKHUXMOKLPDAKM-KLXURFKVSA-N calcium;3-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid;(2,5-dioxoimidazolidin-4-yl)urea Chemical compound [Ca+2].NC(=O)NC1NC(=O)NC1=O.OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O RKHUXMOKLPDAKM-KLXURFKVSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- DCFWIZFONLVPKL-KSSASCOMSA-N (2,5-dioxoimidazolidin-4-yl)urea;(2s,3r,4s,5r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound NC(=O)NC1NC(=O)NC1=O.OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O DCFWIZFONLVPKL-KSSASCOMSA-N 0.000 description 3
- LWNZJCOLRQMXHS-UHFFFAOYSA-N 2-acetamido-4-methylsulfanylbutanoic acid;(2,5-dioxoimidazolidin-4-yl)urea Chemical compound NC(=O)NC1NC(=O)NC1=O.CSCCC(C(O)=O)NC(C)=O LWNZJCOLRQMXHS-UHFFFAOYSA-N 0.000 description 3
- DCWBLFMYZJBXPI-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;(2,5-dioxoimidazolidin-4-yl)urea Chemical compound NC(=O)NC1NC(=O)NC1=O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 DCWBLFMYZJBXPI-UFLZEWODSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229920002230 Pectic acid Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 3
- 235000010081 allicin Nutrition 0.000 description 3
- -1 allyl sulfocyanate Chemical compound 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000010318 polygalacturonic acid Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000009724 venous congestion Effects 0.000 description 3
- UBJVUCKUDDKUJF-UHFFFAOYSA-N Diallyl sulfide Chemical compound C=CCSCC=C UBJVUCKUDDKUJF-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 230000001632 homeopathic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 208000027185 varicose disease Diseases 0.000 description 2
- XUHLIQGRKRUKPH-GCXOYZPQSA-N Alliin Natural products N[C@H](C[S@@](=O)CC=C)C(O)=O XUHLIQGRKRUKPH-GCXOYZPQSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010056717 Varicophlebitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZXRRHFSTAFVGOC-UHFFFAOYSA-N [AlH3].[K] Chemical compound [AlH3].[K] ZXRRHFSTAFVGOC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical compound OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 description 1
- 235000015295 alliin Nutrition 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- JYADQTVYMVQCKM-UHFFFAOYSA-J aluminum sodium tetrachlorate Chemical compound [Al+3].Cl(=O)(=O)[O-].[Na+].Cl(=O)(=O)[O-].Cl(=O)(=O)[O-].Cl(=O)(=O)[O-] JYADQTVYMVQCKM-UHFFFAOYSA-J 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007632 sclerotherapy Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000033772 system development Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ARSRJFRKVXALTF-UHFFFAOYSA-N tricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 ARSRJFRKVXALTF-UHFFFAOYSA-N 0.000 description 1
- CMPNIWQMRYYTMK-UHFFFAOYSA-O tricetinidin Natural products [O+]=1C2=CC(O)=CC(O)=C2C=CC=1C1=CC(O)=C(O)C(O)=C1 CMPNIWQMRYYTMK-UHFFFAOYSA-O 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medicinal beauty cosmetic for treating varicosis and a preparing method thereof. The medicinal beauty cosmetic comprises 6 to 40 wt% of at least one kind of water soluble aluminum salt used as an active component, 1 to 15 wt% of onion plant extract, 0.01 to 2.0 wt% of allantoin and/or allantoin salt and/or allantoin additive compound, and emulsion or ointment, etc. as the rest, which is used as a carrier or a substrate. The product can be effectively used for simultaneously treating primary and concurrent varicose vein dermatosis and can greatly relieve dermatitis and ulcers of concurrent varicose vein.
Description
The invention relates to a kind of therapeutic medical cosmetics and production method thereof, these cosmetics comprehensively approach are used to prevent and treat venous engorgement, varicophlebitis and concurrent various dermatosis.
The adult of known nearly 15-17% suffers from the varicosis that shallow-layer Venous system development of deformation gets up.Significantly the varicosis disease symptoms is venous congestion and extension and has some curves, and Secondary cases variation such as thinning of skin and become livid purple color, and the both legs vein upholds swelling, fibre modification takes place and the end forms ulcer slightly.
Cause wall of vein structure, permeability and elasticity decay owing to enter the venous congestion of primary varicose veins disease and Secondary cases disease, become very poor, increased thrombosis thereupon to the blood supply of domain of dependence.
Nbjective symptom can cause subjective symptom,, burns pruritus sensation, skin anxiety, spasm, pain etc. as patient's sensation " lower limb is very heavy ".
The most common treatment method of varicose veins of the lower extremity disease is surgical operation class excision (ligation or remove) and sclerotherapy.The compression set therapy can produce the closed and long-term fibre modification of adhesive vein.After operation, varicosis regular meeting recurs once more.
Early stage before varicosis concurrency symptom produces can adopt the treatment of non-surgery operation method, for example in the near region of foot or wear elasticity stockings or bundle binder on lower limb.Raising both legs can also make vein oppress blood flow easily.Heal with medicine and have only limited probability.It is dangerous being applied to the medicine that contains steroid, thereby does not advocate to adopt.
The Drug therapy of some non-surgery operations, normal cream class or the emulsion class that contains aluminium potassium sulfate of using.With the aluminium potassium sulfate that is dispersed in the water base ointment, can play contraction.Be used for the treatment of coagulant and other medicine of skin deformation, be shown in U.S. Patent No. 4,331,653 and 4,626,433, reach Hungary's product pointed in hungarian patent No.208251, these coagulant and other medicine all contain this inorganic salt.
The ointment that contains aluminium potassium sulfate can have the improvement of quite big degree to the early symptom of varicosis, but they also are not enough to treat complicated concurrent varicosis effectively, alleviate the loss of skin elasticity and vulnerability and cure the ulcer that both legs exist simultaneously.Their chronic administration can cause skin allergy simultaneously, although therapeutic effect is arranged.
No matter the effectiveness of the non-surgery operation of varicosis treatment is that overall administration or topical can both obtain basic improvement, if adopt the suitable active agent, the extract from plant of natural origin and situation about using with appropriate format under.No matter from patient's healthiness condition and ability to work or to socioeconomic promotion, Drug therapy has more advantage than surgical operation and operation back in hospital care.
Use has the medicament of contraction, can make the venous organizational structure of swelling obtain many improvement.As you know, different types of aluminum vitriol has this effect, can make wall of vein obtain contraction and enhancing simultaneously, improves blood circulation and alleviate edema.
Employing has the natural source medicament of recovery and anti-inflammatory effect, also can further improve the secondary disease main body symptom relevant with other of varicosis.
Allantoin (allantoin) has good skin rehabilitative action, for a long time just known dawn on homeopathic therapeutic method (homeopathy) and cosmetics and pharmaceutical industries.Allantoin (Acetic acid,oxo-,monohydrate diureide, 5-uride hydantoin) can make to be organized easy cicatrization and forms new cell (referring to Manual of cosmetics, Technical publishing House, 1994).Allantoin can make skin smooth and softness, and it has the healing effect and tissue is had regeneration wound.It also has the effect of anesthesia and counter-stimulus.Allantoin can promote keratin to disperse in skin and make its moistening comprehensive function, can make skin become smooth and high resilience (Mecca S.B.Soap, parfum cosmetics, 1976 (10) 434-443).
Herbaceous plant Allium Bulbus Allii Cepae (Allium cepae) extract is that extract Bulbus Allii Cepae element (extractcepae) has excellent antibiotic and irritation effect.The useful physiological action of the Allium Bulbus Allii Cepae element almost homeopathic therapeutic method aspect all over the world is common to all.Its ethanol extraction is usually used in cosmetics.It is applicable to regeneration, the sterilization of skin injury and is used to expose or the skin surface of irriate eases the pain.Its activating agent is a kind of volatile oil, its composition has diallyl sulfide, Tricetin (quercetin), citric acid, inuloid (inulin), pectin, pentose, allyl sulfocyanate etc., and (the Romvary work: Fuszerek Konyve one is the book of a flavoring agent, Budapest publishing house, 1976,17-145).By the useful effect of the alliin in the ethanol extraction Bulbus Allii Cepae element, allicin, ring allicin, back allicin (postallicin), ribosidoadenine, the elasticity of blood vessel wall and blood circulation can improve.
The objective of the invention is to develop a kind of medicinal product of the shortcoming that has no side effect.This product contains herbaceous plant extract Bulbus Allii Cepae, skin regeneration material allantoin and blood vessel is had the aluminum vitriol of contraction and anti-inflammatory effect, but does not have the steroid composition.It can prevent and cure varicosis and the pain of following thereof and have severe complications such as thinning of skin, varicose hyperemia, fibre modification and leg ulcer well to the skin regeneration of damage.
Another object of the present invention is when this medicinal product is coated on the cirsoid skin surface for a long time, and the skin regeneration effect is arranged, and unlikelyly causes undesirable side effect, and people are glad to be used and do not stay stain on clothes and bedding.
The production method that also has another purpose to provide a kind of new compositions medical treatment ointment of the present invention, its production method is simple, with low cost, simultaneously easy to use, the plant extract activating agent, organic active agent and the aluminum vitriol that contain skin nursing and skin regeneration of this ointment, can slow down or eliminate varicosis and Secondary cases disease such as thinning of skin, dermatitis or ulcer.
The invention provides a kind of medical and beauty treatment cosmetic product, it is a kind of compositions, wherein contain at least a water-soluble aluminum salt as (A) 6-40 (weight) % of activating agent or active constituent, (B) the allium extract Bulbus Allii Cepae element of 1-15 (weight) %, (C) allantoin and/or the allantoin salt of 0.01-2.0 (weight) % and/or allantoin additive compound Allantoin biotin. and/or allantoin-calcium pantothenate and/or allantoin-acetyl methionine and/or allantoin-ascorbic acid and/or the allantoin-galacturonic acid and/or the Allantoin polygalacturonic acid etc. of other skin regeneration material are arranged, and mix use with emulsion or ointment as (D) carrier or substrate.The consumption of this carrier or substrate (weight) is all the other weight percent except that above-mentioned active constituent.Above said water-soluble aluminum salt comprise aluminium potassium sulfate, acetic acid-sodium tartrate aluminum, aluminum ammonium sulfate etc.Said allantoin salt can be selected allantoic acid aluminum (Aluminium allantoinate) and chlorine hydroxyl allantoic acid aluminum (aluiniumchlorhydroxy allantoinate) etc. for use.
The present invention also provides a kind of manufacture method of medicinal cosmetics as follows:
To belong to Bulbus Allii Cepae with the alcohol extraction fitoncidin (cepae) of going abroad from herbaceous plant earlier, from above-mentioned these active constituents, select required each component for use then, be mixed together, mix with (D) base or carrier at last, make the finished product of emulsion or ointment.
Above-mentioned allantoin can increase the binding ability of tissue and water, the skin surface that can heal and be rubbed He be upset simultaneously.Allantoin is a kind of amphoteric compound, can with various medicaments in conjunction with forming metallic salt and different reactive compounds, be used for coating and treatment dermatosis.If allantoin is used in combination with other chemical compound, perhaps use with the allantoin salt, then the skin recovery effect of allantoin can further improve and strengthen.Effective allantoin salt is just like allantoic acid aluminum, chlorine hydroxyl allantoic acid aluminum, or allantoin-acetyl methionine, or Allantoin biotin., or allantoin-calcium pantothenate, or allantoin-galacturonic acid or Allantoin polygalacturonic acid etc.
Since aluminum salt, herbaceous plant Bulbus Allii Cepae extract and allantoin in conjunction with synergism, blood vessel wall is shunk, reduce edema, blood circulation is improved, and because the skin nursing effect of these medicaments, regeneration and disinfective action, the general state of skin surface can take a turn for the better.The subjective painful minimizing that blood circulation in the vein improves and skin surface is felt simultaneously.
This product also has facilitation to rehabilitation course.Restoring purpose for health can be coated to human body surface with this product, is to adopt aqueous ointment form, and this ointment is identical with treatment usefulness.As water-soluble aluminum salt, can use aluminium potassium sulfate, acetic acid-sodium tartrate aluminum, aluminum ammonium sulfate.
Medical and beauty treatment cosmetic product of the present invention is made up of following main active:
(A) water-soluble aluminum salt of at least a type of 6-40 (weight) %;
(B) the plant extract Bulbus Allii Cepae element of 1-15 (weight) %, and
(C) the skin regeneration agent allantoin of 0.01-2.0 (weight) % and/or allantoin salt and or the allantoin additive compound; The product of all prescriptions all contains (D) ointment of regulation or emulsion as carrier or base.
Wherein said allantoin salt is to be selected from allantoic acid aluminum and/or chlorine hydroxyl allantoic acid aluminum; Said allantoin additive compound is to be selected from Allantoin biotin., allantoin-calcium pantothenate, allantoin-acetyl methionine, allantoin-ascorbic acid, allantoin-galacturonic acid, Allantoin polygalacturonic acid; Said water-soluble aluminum salt is to be selected from aluminium potassium sulfate, acetic acid-sodium tartrate aluminum, aluminum ammonium sulfate.
The method for making of the medicinal cosmetics of the present invention is as follows:
1. the preparation of plant extract Bulbus Allii Cepae element (cepae): 4 days (96 hours) of alcoholic solution (it consists of the water of 40 weight % and 90% (weight) ethanol of 60 weight %) dipping that herbaceous plant (herb) the Allium Bulbus Allii Cepae of 15 (weight) % accounted for total solution weight 60 weight % with the ethanol of 90 weight %, then leaching liquid is filtered, the dry-matter content of extract is 4.5 (weight) %;
2. the apolegamy of active constituent: from above-mentioned (A), (B) and (C) select needed component for use in the active constituent, it is at least a water-soluble aluminum salt (A) of 6-40 (weight) %, the allantoin of the extract Bulbus Allii Cepae element (B) of 1-15 (weight) % and 0.01-2.0 (weight) % and/or allantoin salt and/or other allantoin additive compound (C) at room temperature add water together and mix;
3. machine-shaping: " ungentum hydrophilicum nonionicum (USP XXIII) or aqueous solution ungentum hydrosum mix at normal temperatures, make emulsion or ointment with (D) base or for example known Hungary of carrier aqueous emulsion ointment " ungentum emulsifikans aquosum (BP 1988) " or nonionic hydrophilic ointment with above-mentioned each active constituent mixture.The curative effect contrast test observes
Once medical and beauty treatment cosmetics of the present invention and the common drug for the treatment of varicosis had at present been done contrast, evidence product treatment of the present invention varicosis is effectively.They can not only the topical therapeutic varicosis venous congestion and/or blood clotting thrombosis, and superficial veins and telangiectasis are improved, and can also prevent and treat the complication of varicosis and xerosis cutis, attenuation, the perhaps ulcer that occurs of two lower limbs.For the patient who suffers from the varicosis tendency is arranged, apply this medicine and can play preventive effect.
Once 17 routine patients were organized and made experimental observation, wherein 9 women and 8 male, 27.68 years old mean age.The ointment of the sulfur acid potassium aluminum that coating is bought from the market on these patients' a lower limb, and on the another lower limb, be coated with above-mentioned ointment of the present invention.Ointment is coated on the skin surface of suffering from varicosis, twice of every day.No longer be coated with other medicine of applying treatment varicosis.
The symptom that observed patient occurs before the treatment: soak into edema, pruritus, pain, xerosis cutis.After 18 days treatment, the observer thinks that with patients are consistent medicine of the present invention is obviously more effective than the medicine that only contains the aluminum vitriol.Not only varicosis is had improvement, and its complication is had the improvement of quite big degree, this is because the synergistic result of each active ingredient of pharmaceutical composition of the present invention.
Embodiment 1
(10.2 weight) % (or 10.2 grams) aluminium potassium sulfate
(5.0 weight) % (or 5.0 grams) extract Bulbus Allii Cepae element
(1.0 weight) % (or 1.0 grams) allantoin 83.8 (weight) % (or 83.8 grams) ungentum emulsifikans aquosum (BP1988)
Embodiment 20.5 (weight) % (or 0.5 gram) acetic acid-tartaric acid aluminum 9.7 (weight) % (or 9.7 grams) aluminum potassium sulfate 0.5 (weight) % (or 0.5 gram) extract Bulbus Allii Cepae element 0.5 (weight) % (or 0.5 gram) allantoin-calcium pantothenate 88.8 (weight) % (or 88.8 grams) ungentum hydrophilicum nonionicum (USP XXIII)
Embodiment 325.0 (weight) % (or 25 grams) aluminum potassium sulfate 0.2 (weight) % (or 0.2 gram) extract Bulbus Allii Cepae element 0.1 (weight) % (or 0.1 gram) allantoin calcium pantothenate 74.7 (weight) % (or 74.7 grams) ungentum hydrophilicum nonionicum (USP XXIII)
Embodiment 45.0 (weight) % (or 5.0 grams) sodium chlorate aluminum 5.0 (weight) % (or 5.0 grams) acetic acid-tartaric acid aluminum 2.0 (weight) % (or 2.0 grams) extract Bulbus Allii Cepae element 0.5 (weight) % (or 0.5 gram) allantoin 87.5 (weight) % (or 87.5 grams) ungentum cmulsifikans aquosum (BP1988)
Claims (9)
1. medicinal cosmetics for the treatment of varicosis is characterized in that containing following three class active constituents:
(A) at least a water-soluble aluminum salt of 6-40 weight %;
(B) the allium extract Bulbus Allii Cepae element of 1-15 weight %, this Bulbus Allii Cepae is plain to account for total solution weight 60 weight % for the ethanol with 90 weight % alcoholic solution be allium Bulbus Allii Cepae dipping 4 days promptly 96 hours, filters then, drying and making.
(C) allantoin of 0.01-2.0 weight % and/or allantoin salt, and
(D) substrate or carrier or excipient are emulsion or ointment or ointment form, and its consumption is all the other percentage by weights except that (A), (B), (C).
2. the medicinal cosmetics of treatment varicosis as claimed in claim 1 is characterized in that (A) component water-soluble aluminum salt is preferably from aluminium potassium sulfate and/or acetic acid-sodium tartrate aluminum and/or aluminum ammonium sulfate.
3. the medicinal cosmetics of treatment varicosis as claimed in claim 1 is characterized in that allantoin salt is preferably from allantoic acid aluminum and/or chlorine hydroxyl allantoic acid aluminum in (C) component.
4. the medicinal cosmetics of treatment varicosis as claimed in claim 1 is characterized in that (A) component contains aluminium potassium sulfate and/or acetic acid-sodium tartrate aluminum and/or the aluminum ammonium sulfate of 6-40 weight %.
5. the medicinal cosmetics of treatment varicosis as claimed in claim 3 is characterized in that (C) component contains allantoic acid aluminum and/or the chlorine hydroxyl allantoic acid aluminum of 0.01-2.0 weight %.
6. the medicinal cosmetics of treatment varicosis as claimed in claim 1 is characterized in that said substrate can be preferably from ordinary emulsion ointment, or hydrophilic nonionic ointment or aqueous solution ointment.
7. the medicinal cosmetics of treatment varicosis as claimed in claim 1, the each component ratio that it is characterized in that filling a prescription is:
(A) 10.2 weight % or 10.2 gram aluminium potassium sulfates,
(B) 5.0 weight % or 5.0 gram extract Bulbus Allii Cepae elements,
(C) 1.0 weight % or 1.0 gram allantoin,
(D) 83.8 weight % or 83.8 gram aqueous emulsion ointment.
8. method for making for the treatment of the medicinal cosmetics of varicosis is characterized in that following steps:
(1) extract Allium Bulbus Allii Cepae element: the alcoholic solution that accounts for total solution weight 60 weight % with the ethanol of 90 weight % was with allium Bulbus Allii Cepae dipping 4 days, and promptly 96 hours, filtration, drying obtained the Bulbus Allii Cepae element then;
(2) assembly of each active ingredient: water-soluble aluminum salt such as aluminium potassium sulfate and/or acetic acid-sodium tartrate aluminum and/or the aluminum ammonium sulfate of getting 6-40 weight %, the allantoin of the Bulbus Allii Cepae element of 1-15 weight % and 0.01-2.0 weight % and/or allantoic acid aluminum and/or chlorine hydroxyl allantoic acid aluminum at room temperature add water and mix; Again with mixture and the carrier or the substrate mixed-forming of each active constituent.
9. the purposes in described cosmetics of claim 1 medicine aspect preparation treatment varicosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98126710A CN1095375C (en) | 1998-12-30 | 1998-12-30 | Medicated cosmetics capable of being used to treat primary and secondary varicose vein simultaneously and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98126710A CN1095375C (en) | 1998-12-30 | 1998-12-30 | Medicated cosmetics capable of being used to treat primary and secondary varicose vein simultaneously and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1258532A CN1258532A (en) | 2000-07-05 |
| CN1095375C true CN1095375C (en) | 2002-12-04 |
Family
ID=5229746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98126710A Expired - Fee Related CN1095375C (en) | 1998-12-30 | 1998-12-30 | Medicated cosmetics capable of being used to treat primary and secondary varicose vein simultaneously and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1095375C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105709027A (en) * | 2014-08-15 | 2016-06-29 | 曹哲 | Ointment for treating varicosity and phlebitis as well as preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1043628A (en) * | 1987-02-09 | 1990-07-11 | 拉斯兹洛·汉科 | Composition for alleviating varicose veins and its preparation method |
-
1998
- 1998-12-30 CN CN98126710A patent/CN1095375C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1043628A (en) * | 1987-02-09 | 1990-07-11 | 拉斯兹洛·汉科 | Composition for alleviating varicose veins and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1258532A (en) | 2000-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9814750B2 (en) | Use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer | |
| CN108853312B (en) | Polycinnamic alcohol external gel and preparation method thereof | |
| CN102917719B (en) | Kit of medicines for treating and/or preventing skin ulcers | |
| CN1095375C (en) | Medicated cosmetics capable of being used to treat primary and secondary varicose vein simultaneously and its preparation | |
| US5576329A (en) | Method for treating tendon or joint inflammation with papaverine HCL | |
| CN1634429A (en) | Medicine composition for treating furuncle, abscess, carbuncle, furuncle, burn and scald | |
| JPH08500343A (en) | Treatment method using cesium ion | |
| RU2246959C2 (en) | Antiinflammatory and wound-healing ointment | |
| CN107456567A (en) | Moist heel cream and preparation method thereof is repaired in a kind of anticracking detumescence | |
| RU2818756C1 (en) | Hyaluronic gel for trophic ulcer healing with dimexidum | |
| WO2000050085A2 (en) | Oil-in-water emulsion for the use as medicament or for producing a medicament | |
| RU2236840C2 (en) | Curative-cosmetic cream (variants) | |
| RU2817358C1 (en) | Gel for healing of trophic ulcers hyaluronic acid with msm | |
| CN104606340A (en) | Purely natural traditional Chinese medicine repair skin and tissue cream | |
| CN108904638A (en) | A kind of multiduty external application combination drug and application | |
| CN119868435B (en) | Traditional Chinese medicine composition and traditional Chinese medicine ointment for treating old ankle sprain | |
| RU2355411C1 (en) | Wound- healing ointment | |
| CN103655854A (en) | External application medicine for treating phlebitis caused by intravenous infusion and using method thereof | |
| US6395779B1 (en) | Method of treatment using peroxidized lipids | |
| MX2013004077A (en) | Pharmaceutical composition based on centella asiatica (hydrocotyle asiatica l.) for treating lower limbs ulcers. | |
| CN1079237C (en) | Dog bone scald medicine | |
| CN1939313A (en) | Externally-applied preparation for treating trauma | |
| CN1141967C (en) | Externally applied Chinese medicine oil prepn for treating burns and scalds | |
| CN1110316C (en) | Black plaster and preparing process thereof | |
| CN117442683A (en) | A traditional Chinese medicine composition and ointment for treating burns and scalds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent for invention or patent application | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN AIHUA FRESHENER CO., LTD. TO: TIANJIN FOLUOLIN CHEMICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 301714 Tianjin city Wuqing District Road No. 2 high Hexi Wu Town Applicant after: Folurin Chemical Co Ltd, Tianjin Address before: In 30000 Tianjin city Wuqing County Road No. 2 Wu Zhen Gao Applicant before: Tianjin Aihua Freshener Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20021204 Termination date: 20100201 |